by Raynovich Rod | Jul 24, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
Movers in Rayno Diagnostics and Tools Stocks On a lackluster day in the market two of our picks were up big,two others exceeded one year highs. Illumina (ILMN $81) was up 10% on earnings to an all time high recovering from its downdraft in 2011. Revenues were up 23%...
by Raynovich Rod | Jul 16, 2013 | Biopharmaceuticals
Biotech Stocks Take A Breather: NASDAQ off 0.3% at 3597 A little profit taking has set in after it seemed that the market would roar all summer. From the action in mid-cap biopharma stocks it looks like hedge funds are taking some off among high flyers.NASDAQ has been...
by Raynovich Rod | Jun 25, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Global Economic Picture Not Good-Healthcare A Laggard on Rally Day Strong housing and durable goods data supported the rally today taking the S&P up 0.95% and NASDAQ up 0.82%. Comments from the China’s Central Bank helped a recovery from a free fall in the...
by Raynovich Rod | Jun 20, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Rayno Diagnostics and Tools Portfolio Prices as of 5/29/13 Top 2013 Winners: ABAX, ALR, CSII, GHDX, ILMN, TMO, VRML Sector high was in mid-May Less volatile than biopharma but more dependent on earnings Five companies on focus list were acquired over 3 years...
by Raynovich Rod | Jun 13, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
6/14 Supreme Court Ruling on Genetic Tests Takes Down Myriad Stock (MYGN $30.50)-Off Another 3% but still up 13% YTD. The Supreme Court ruling opens up competition for Myriad’s breast cancer tests as well as other genetic disease markers.The immediate reaction...
by Raynovich Rod | Jun 11, 2013 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
Life Science Stocks Holding Up Amidst Volatility-Stay Cautious Biotech stocks are mixed today as volatility from currency moves and violence in Turkey and the Middle East gives pause to investors. Bonds have corrected almost 5% prompting an exit from bond funds as the...
by Raynovich Rod | May 29, 2013 | Clinical Diagnostics and Tools
Rayno Diagnostics and Tools Portfolio Rayno Life Science top picks were up 20 to 53% beating the NASDAQ and S&P. Five new stocks were added in 2013: BG Medicine (BGMD), Genomic Health (GHDX), Hologic (HOLX), Vermillion (VRML). One major trend is larger cap...
by Raynovich Rod | May 28, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
Impressive Rally in Diagnostics and Tools Stocks The NASDAQ rally is beginning to fade now up only 17 pts after hitting a high of 3510 at 10 am EDT. However many Life Science Tools and Diagnostics stocks are having a strong day. We recently featured 3 micro-cap...
by Raynovich Rod | May 15, 2013 | BIOgraph, Clinical Diagnostics and Tools
Biomarker Products for Cardiovascular Disease and Cancer This is the third article on Emerging Biomarker Companies. See 11/15/12 Update The synergies between diagnostics and drugs are growing as more treatment options require better data for cost-effective, targeted...
by Raynovich Rod | May 9, 2013 | BIOgraph, Clinical Diagnostics and Tools
Vermillion Gets Equity Infusion from Oracle Partners, Others: VRML Soars 36% By popular demand and continuing interest in three emerging micro-cap stocks we are updating coverage. This is triggered by news that saavy life science investors are making an initial...
